Saturday, June 25, 2016
Three Years Ago...
In June 2013, in Association for Molecular Pathology v. Myriad Genetics (No. 12-398), the court unanimously ruled that, "A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated," invalidating Myriad's patents on the BRCA1 and BRCA2 genes.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment